GW&K Investment Management LLC boosted its holdings in shares of Globus Medical Inc (NYSE:GMED) by 35.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,447,134 shares of the medical device company’s stock after acquiring an additional 378,211 shares during the quarter. Globus Medical accounts for 1.0% of GW&K Investment Management LLC’s portfolio, making the stock its 10th biggest holding. GW&K Investment Management LLC owned about 1.46% of Globus Medical worth $73,977,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Janus Henderson Group PLC raised its position in Globus Medical by 83.1% during the 2nd quarter. Janus Henderson Group PLC now owns 6,179,600 shares of the medical device company’s stock valued at $261,397,000 after purchasing an additional 2,803,797 shares in the last quarter. Nuance Investments LLC raised its position in Globus Medical by 307.4% during the 2nd quarter. Nuance Investments LLC now owns 1,316,057 shares of the medical device company’s stock valued at $55,669,000 after purchasing an additional 993,056 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in Globus Medical during the 2nd quarter valued at $29,363,000. Pembroke Management LTD bought a new stake in Globus Medical during the 2nd quarter valued at $13,495,000. Finally, Invesco Ltd. raised its position in Globus Medical by 73.1% during the 2nd quarter. Invesco Ltd. now owns 627,072 shares of the medical device company’s stock valued at $26,526,000 after purchasing an additional 264,790 shares in the last quarter. Institutional investors own 68.00% of the company’s stock.
In related news, SVP Kelly Huller sold 3,000 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $52.90, for a total transaction of $158,700.00. Following the transaction, the senior vice president now directly owns 6,384 shares of the company’s stock, valued at approximately $337,713.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David D. Davidar sold 50,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $49.33, for a total value of $2,466,500.00. Following the transaction, the director now directly owns 754,775 shares in the company, valued at $37,233,050.75. The disclosure for this sale can be found here. Insiders own 24.97% of the company’s stock.
Shares of GMED traded up $0.98 during trading hours on Friday, hitting $55.72. The company had a trading volume of 585,132 shares, compared to its average volume of 578,325. The company has a market capitalization of $5.24 billion, a PE ratio of 33.37, a price-to-earnings-growth ratio of 2.74 and a beta of 0.95. Globus Medical Inc has a one year low of $38.01 and a one year high of $56.34. The company’s fifty day moving average price is $51.06 and its two-hundred day moving average price is $46.42.
Globus Medical (NYSE:GMED) last released its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.01. The firm had revenue of $196.22 million during the quarter, compared to analyst estimates of $185.86 million. Globus Medical had a return on equity of 13.29% and a net margin of 19.30%. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.39 EPS. Sell-side analysts predict that Globus Medical Inc will post 1.71 earnings per share for the current year.
Globus Medical Company Profile
Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.
Read More: How to Use the New Google Finance Tool
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.